読み込み中
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.
前日終値
$1.83
−$0.04 · -2.14%
時間外
$1.8577
+$0.0277 · +1.51%
10月12日 19:59 ET
日中の時刻はETです。市場データは遅延する場合があります。
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.
日中レンジ
現在 $1.83
52週レンジ
現在 $1.83
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
35
割高
センチメント
69
強気
リスク
44
やや高いリスク
モメンタム
76
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.
日中レンジ
現在 $1.83
52週レンジ
現在 $1.83
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 研究開発 | 3267.2万 USD | 1270.9万 USD | 322.9万 USD | 537.74万 USD | 2514.74万 USD |
| 販売・一般管理 | 2371.3万 USD | 678.5万 USD | 500.5万 USD | 567.52万 USD | 758.08万 USD |
| 営業費用 | 5638.5万 USD | 1949.4万 USD | 823.4万 USD | 1105.26万 USD | 3272.82万 USD |
| 受取利息 | 381.9万 USD | 191.4万 USD | — | — | — |
| 支払利息 | — | 2.3万 USD | 2.4万 USD | 4443 USD | 949 USD |
| 減価償却費と償却費 | — | — | 8000 USD | 11.33万 USD | 10.9万 USD |
| 営業利益 | −5638.5万 USD | −1949.4万 USD | −823.4万 USD | −1105.26万 USD | −3272.82万 USD |
| 純利益 | −5259.9万 USD | −1760.2万 USD | −771.1万 USD | −1104.79万 USD | −3247.44万 USD |
会社概要が更新されました 2026年10月13日.
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
iShares Russell 2000 ETFIWM174.15万0.00%787.4億 USD0.19%$277.9-0.37%
Vanguard Morningstar Total Stock Market ETFVTI156.82万0.00%2.3兆 USD0.03%$381.57-0.10%
Vanguard Extended Market ETFVXF51.47万0.00%954億 USD0.05%$233.52-0.63%
Vanguard Russell 2000 ETFVTWO26.53万0.00%180億 USD0.06%$112.27-0.35%
iShares Micro-Cap ETFIWC21.37万0.02%13.17億 USD0.60%$181.66-0.73%
Fidelity Enhanced Small Cap ETFFESM11.58万—64.1億 USD0.28%$45.24-0.48%
ALPS Medical Breakthroughs ETFSBIO8.82万0.05%1.91億 USD0.50%$53.85-2.16%
Dimensional - US Core Equity 2 ETFDFAC6.14万0.00%885.96億 USD0.21%$45.31-0.04%iShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCFidelity Enhanced Small Cap ETFFESMALPS Medical Breakthroughs ETFSBIODimensional - US Core Equity 2 ETFDFACAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
